Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced
Atlas ("Atlas" or the "Company") (NYSE: ATCO) announced today that its board of directors (the "Board") has received a non-binding proposal letter, dated August 4, 2022, from Poseidon Acquisition Corp.